In patients with chronic heart failure, vasodilating beta-blockers may be preferable to avoid the adverse metabolic effects and risk of new-onset diabetes associated with other beta-blockers.
No takes yet. Share an insight, caveat, or question.
May favor vasodilating beta-blockers to limit diabetes risk; leaves open randomized confirmation in heart failure.
Kostis et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: